Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Pathologies Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Niños Sanos, Familia Sana - A Multi-Intervention Program to Prevent Childhood Obesity in Mexican-Heritage Children in Rural California

NCT01900613
View directory record Official record
Conditions
Obesity
Interventions
Ninos Sanos Familia Sana
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
3 Years to 8 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 3, 2026, 5:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

NCT06973720
View directory record Official record
Conditions
Obesity, Overweight or Obesity
Interventions
MET097, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Hollywood, Florida • Tampa, Florida • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780
View directory record Official record
Conditions
Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions
Linvoseltamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
8
States / cities
Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

NCT01874366
View directory record Official record
Conditions
Overweight, Diabetes Mellitus Type 2 in Obese
Interventions
P11187, Placebo
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Palliative Oxygen for the Relief of Breathlessness

NCT00327873
View directory record Official record
Conditions
Dyspnea
Interventions
Oxygen, Medical Air
Other
Lead sponsor
National Health and Medical Research Council, Australia
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2009 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Phase 1 Interventional

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma

NCT00645970
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Morbidity After Diagnosis and Treatment of Breast Cancer Patients

NCT00027118
View directory record Official record
Conditions
Breast Cancer, Shoulder, Lymphedema, Fatigue
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 85 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 3, 2026, 5:34 PM EDT
Completed No phase listed Observational

Speech Accessibility Project

NCT05889260
View directory record Official record
Conditions
Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions
Not listed
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Denver, Colorado • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients

NCT00598559
View directory record Official record
Conditions
Acute Pain, Fever
Interventions
IV Acetaminophen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 85 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Arcadia, California • Glendale, California • Laguna Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00624286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
118
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Arista for ALT Donor Sites to Reduce Drain Output

NCT02477774
View directory record Official record
Conditions
Seroma
Interventions
ARISTA
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 3, 2026, 5:34 PM EDT
Terminated Phase 2 Interventional Results available

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

NCT00837824
View directory record Official record
Conditions
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions
Fabrazyme (agalsidase beta)
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
9
States / cities
Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 3, 2026, 5:34 PM EDT
Not listed Phase 3 Interventional

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

NCT00628680
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
AAT-023 solution (Zuragen), Heparin
Device · Drug
Lead sponsor
Ash Access Technology
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
22
States / cities
Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 3, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Development of a Multi-sensory Rehabilitation Program for People With Ultra Low Vision

NCT05028712
View directory record Official record
Conditions
Low Vision Blindness, Visual Impairment, Quality of Life, Functional Visual Loss
Interventions
Visual Information Training, Multimodal training
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
12 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 3, 2026, 5:34 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

NCT03704298
View directory record Official record
Conditions
Relapsed/Refractory Large B-cell Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Drug · Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 3, 2026, 5:34 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

NCT02075463
View directory record Official record
Conditions
Anemia, Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Azusa, California • Glendale, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Terminated Not applicable Interventional Results available

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

NCT00399893
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
5 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 3, 2026, 5:34 PM EDT
Not yet recruiting Not applicable Interventional

Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood

NCT07446907
View directory record Official record
Conditions
Obesity & Overweight, Sarcopenia
Interventions
High Protein Diet Counceling, Standard Protein Diet Counceling, Protein Supplement, Supervised Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 3, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

NCT01537432
View directory record Official record
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
secukinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 3, 2026, 5:34 PM EDT